Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.

Jayasekara H, MacInnis RJ, Chamberlain JA, Dite GS, Leoce NM, Dowty JG, Bickerstaffe A, Win AK, Milne RL, Giles GG, Terry MB, Eccles DM, Southey MC, Hopper JL.

Int J Cancer. 2019 Feb 16. doi: 10.1002/ijc.32214. [Epub ahead of print]

PMID:
30771221
2.

The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.

Sopik V, Sun P, Narod SA.

Breast Cancer Res Treat. 2017 Sep;165(2):391-402. doi: 10.1007/s10549-017-4333-2. Epub 2017 Jun 10.

PMID:
28601929
3.

Body weight correlates with mortality in early-stage breast cancer.

Enger SM, Greif JM, Polikoff J, Press M.

Arch Surg. 2004 Sep;139(9):954-58; discussion 958-60.

PMID:
15381612
4.

Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.

Jatoi I, Chen BE, Anderson WF, Rosenberg PS.

J Clin Oncol. 2007 May 1;25(13):1683-90. Epub 2007 Apr 2.

PMID:
17404367
5.

Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.

Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G, Jones L, Bliss J, Eccles D; POSH Study Steering Group.

J Natl Cancer Inst. 2013 Jul 3;105(13):978-88. doi: 10.1093/jnci/djt134. Epub 2013 May 30.

PMID:
23723422
6.

Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics.

Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, Czene K.

J Clin Oncol. 2011 Oct 20;29(30):4014-21. doi: 10.1200/JCO.2010.32.6462. Epub 2011 Sep 12.

PMID:
21911717
7.
8.

Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.

Yu KD, Wu J, Shen ZZ, Shao ZM.

J Clin Endocrinol Metab. 2012 Dec;97(12):E2201-9. doi: 10.1210/jc.2012-2423. Epub 2012 Sep 19.

PMID:
22993034
9.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804. Erratum in: Lancet. 2017 May 13;389(10082):1884.

10.

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.

Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L.

BMC Cancer. 2013 May 4;13:225. doi: 10.1186/1471-2407-13-225.

11.

Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.

Dignam JJ, Wieand K, Johnson KA, Raich P, Anderson SJ, Somkin C, Wickerham DL.

Breast Cancer Res Treat. 2006 Jun;97(3):245-54. Epub 2005 Dec 6.

PMID:
16331345
12.
13.

Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.

14.

Improvements in US Breast Cancer Survival and Proportion Explained by Tumor Size and Estrogen-Receptor Status.

Park JH, Anderson WF, Gail MH.

J Clin Oncol. 2015 Sep 10;33(26):2870-6. doi: 10.1200/JCO.2014.59.9191. Epub 2015 Jul 20.

15.

Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study.

Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K.

Cancer Res. 2014 Aug 1;74(15):4065-77. doi: 10.1158/0008-5472.CAN-13-2679.

16.

Estrogen receptor quantitative measures and breast cancer survival.

Hill DA, Barry M, Wiggins C, Nibbe A, Royce M, Prossnitz E, Lomo L.

Breast Cancer Res Treat. 2017 Dec;166(3):855-864. doi: 10.1007/s10549-017-4439-6. Epub 2017 Aug 19.

17.

Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.

Luyeye Mvila G, Batalansi D, Praet M, Marchal G, Laenen A, Christiaens MR, Brouckaert O, Ali-Risasi C, Neven P, Van Ongeval C.

Breast. 2015 Oct;24(5):642-8. doi: 10.1016/j.breast.2015.07.031. Epub 2015 Aug 14.

PMID:
26279132
18.

Androgen receptor expression and breast cancer mortality in a population-based prospective cohort.

Elebro K, Bendahl PO, Jernström H, Borgquist S.

Breast Cancer Res Treat. 2017 Oct;165(3):645-657. doi: 10.1007/s10549-017-4343-0. Epub 2017 Jun 22.

19.

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women.

Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss LK, Malone KE, Burkman RT, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L.

Breast Cancer Res. 2013;15(5):R90.

20.

Supplemental Content

Support Center